Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Inhibitory Effect of Polyclonal Antibodies Against Her3 Extracellular Subdomains on Breast Cancer Cell Lines Publisher Pubmed



Mansourifard S1 ; Ghaedi M1 ; Shokri MR2 ; Bahadori T1 ; Khoshnoodi J1 ; Golsazshirazi F1 ; Jedditehrani M3 ; Amiri MM1 ; Shokri F1, 3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Iran
  2. 2. Department of Immunology, School of Medicine, Iran University of Medical Sciences, Iran
  3. 3. Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran

Source: Asian Pacific Journal of Cancer Prevention Published:2020


Abstract

Objective: Human epidermal growth factor receptor 3 (HER3) is a unique member of the tyrosine kinase receptors with an inactive kinase domain and is the preferable dimerization partner for HER2 which lead to potent tumorigenic signaling. Methods: In this study, the expression plasmids coding for the human HER3 subdomains were transfected into CHO-K1 cells. Produced proteins were characterized by ELISA and SDS-PAGE. Rabbits were immunized and produced polyclonal antibodies (pAbs) that were characterized by ELISA, Immunoblotting and flowcytometry and their inhibitory effects were assessed by XTT on BT-474 and JIMT-1 breast cancer cell lines. Result: The recombinant subdomains were highly immunogenic in rabbits. The pAbs reacted with the recombinant subdomains as well as commercial HER3 and the native receptor on tumor cell membranes and could significantly inhibit growth of Trastuzumab sensitive (BT-474) and resistant (JIMT-1) breast cancer cell lines in vitro. Conclusion: It seems that HER3 extra cellular domains (ECD) induce a strong anti-tumor antibody response and may prove to be potentially useful for immunotherapeutic applications. © This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License.
Related Docs
View other Related Docs
1. A Novel Tumor Inhibitory Hybridoma Monoclonal Antibody With Dual Specificity for Her3 and Her2, Current Research in Translational Medicine (2021)
2. Differential Tumor Inhibitory Effects Induced by Her3 Extracellular Subdomain-Specific Mouse Monoclonal Antibodies, Cancer Chemotherapy and Pharmacology (2022)
3. Polyclonal Antibody Against Different Extracellular Subdomains of Her2 Induces Tumor Growth Inhibition in Vitro, Iranian Journal of Immunology (2017)
4. An In-Silico Approach to Find a Peptidomimetic Targeting Extracellular Domain of Her3 From a Her3 Nanobody, Computational Biology and Chemistry (2017)
5. Differential Effects of Inhibitory and Stimulatory Anti-Her2 Monoclonal Antibodies on Akt/Erk Signaling Pathways, Asian Pacific Journal of Cancer Prevention (2018)
6. Potent Synergistic Anti-Tumor Activity of a Novel Humanized Anti-Her2 Antibody Hersintuzumab in Combination With Trastuzumab in Xenograft Models, Investigational New Drugs (2021)
7. Monoclonal Antibody-Based Therapeutics, Targeting the Epidermal Growth Factor Receptor Family: From Herceptin to Pan Her, Journal of Pharmacy and Pharmacology (2018)
8. Effects of Silibinin on Growth and Invasive Properties of Human Ovarian Carcinoma Cells Through Suppression of Heregulin/Her3 Pathway, Tumor Biology (2016)
Experts (# of related papers)
View all Related Experts
Fazel Shokri (10)
Mohammad Mehdi Amiri (10)
Other Related Docs
9. Potent Anti-Tumor Immune Response and Tumor Growth Inhibition Induced by Her2 Subdomain Fusion Protein in a Mouse Tumor Model, Journal of Cancer Research and Clinical Oncology (2023)
10. A Novel Anti-Her2 Bispecific Antibody With Potent Tumor Inhibitory Effects in Vitro and in Vivo, Frontiers in Immunology (2021)
11. Development of a Novel Inhibitory Chimeric Anti-Her2 Monoclonal Antibody, Iranian Journal of Immunology (2019)
12. Comparison of Different Transient Gene Expression Systems for the Production of a New Humanized Anti-Her2 Monoclonal Antibody (Hersintuzumab), DARU# Journal of Pharmaceutical Sciences (2023)
13. Immunization With Her2 Extracellular Subdomain Proteins Induces Cellular Response and Tumor Growth Inhibition in Mice, Immunotherapy (2018)
14. Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications, Frontiers in Immunology (2017)
15. In Silico and in Vitro Evaluation of a Recombinant Fusion Peptide As a Novel Candidate Vaccine for Egfr-Positive Tumors, Biosciences Biotechnology Research Asia (2015)
16. Dacomitinib, a Pan-Inhibitor of Erbb Receptors, Suppresses Growth and Invasive Capacity of Chemoresistant Ovarian Carcinoma Cells, Scientific Reports (2017)